跳至主要内容
临床试验/NCT05602259
NCT05602259招募中不适用

PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC) (PROTEON).

Centre Hospitalier Universitaire de Liege2 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2022年10月27日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
200
试验地点
2
主要终点
Detection of eosinophils in untreated non-small cell lung cancer patients

研究概览

简要总结

This prospective study will examine eosinophils in various biological materials to compare the detection in those materials and ascertain the prognostic and predictive role of eosinophils in untreated non-small cell lung cancer patient.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • o All stages of NSCLC
  • Stage III-IV NSCLC eligible for ICI treatment
  • 18 years or older; non pregnant women
  • in stage III-IV: no previous ICI and before ICI (mono- or combination therapy) initiation
  • Signed informed consent
  • Clinical, biological and radiological evaluation at the CHU de Liège for at least 6 months following treatment initiation

排除标准

  • Probable noncompliance with the follow-up requirements of the study (psychiatric condition, socio-economic factors)
  • Inclusion in a clinical study contraindicating the enrolment in the PROTEON study

结局指标

主要结局

Detection of eosinophils in untreated non-small cell lung cancer patients

时间窗: Baseline (pre-treatment)

Concentration of eosinophils will be used in various bodily materials as described above.

次要结局

  • Prognostic and predictive value of eosinophils in non-small cell lung cancer patients(Baseline (pre-treatment) and, if immunotherapy, after 3 months of treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Anne Sibille

Dr Anne Sibille

Centre Hospitalier Universitaire de Liege

研究点 (2)

Loading locations...

相似试验